Effectiveness of Ustekinumab for Crohn's Disease
Part of Digestive system clinical trials.
This study looks at how well Ustekinumab (Stelara) works for Crohn's disease in people who started the medication in 2024. Researchers want to understand its real-world benefits and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were first prescribed Ustekinumab (brand name Stelara) sometime in 2024.
- You do not have an active serious infection, such as tuberculosis or hepatitis.
- You are not pregnant or breastfeeding.
- You do not have ulcerative colitis (a different bowel condition) or a history of certain cancers or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with moderate-to-severe Crohn's disease who are starting a newer type of biologic medication called IL-23 inhibitors (guselkumab or risankizumab). Researchers want to understand how well these drugs work in real-world clinical practice and compare their effectiveness to other treatments.
This study follows patients with Crohn's disease or ulcerative colitis who started taking ustekinumab between February 2019 and March 2021, to see how well it works over time.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
This Phase 1 study uses a special camera to track how ustekinumab (a common biologic medicine) spreads in inflamed tissue. It aims to help researchers understand where the drug goes in Crohn’s disease and psoriasis, especially when standard treatments haven’t worked.
This study tailors ustekinumab (Stelara) treatment specifically for people with fistulizing Crohn's disease around the anus. It aims to find the best way to use this medicine to improve symptoms like pain and drainage from fistulas.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.